What is ScitoVation?
ScitoVation operates as a Contract Research Organization (CRO), providing critical services to clients in the pharmaceutical, chemical, food ingredient, and cosmetics industries. The company leverages innovative New Approach Methods (NAMs) to assess the safety and efficacy of various products. By offering custom solutions, ScitoVation assists clients in predicting human safety, understanding compound mechanisms of action, and screening lead compounds, thereby streamlining research processes and reducing costs. Their expertise is particularly noted in advanced technologies such as physiologically based pharmacokinetic (PBPK) modeling and toxicogenomic studies, positioning them as a key player in modern product development and regulatory compliance.
How much funding has ScitoVation raised?
ScitoVation has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in ScitoVation
PPP
Public-Private Partnership
What's next for ScitoVation?
With the recent influx of capital, ScitoVation is poised for significant growth and enhanced service offerings. The large-scale late-stage funding suggests a strategic focus on scaling operations, expanding technological capabilities, and potentially broadening its market reach. This investment will likely enable ScitoVation to further solidify its reputation for providing efficient and cost-effective solutions in product safety and efficacy testing, particularly through its advanced NAMs. The company's trajectory indicates a strong commitment to innovation and meeting the evolving demands of its diverse clientele in the pharmaceutical and chemical sectors.
See full ScitoVation company page
